For three years, people around the world had to face and fight the outbreak of the Coronavirus disease (COVID-19). Nowadays, the virus has rapidly mutated and contagiously spread if humans have other alternative prevention besides vaccines. This option could enhance prevention for the population who refuses the vaccine in another way. This article discusses CBD extract, a remarkable new alternative to prevent COVID-19.

In 2022, Nguyen et al. demonstrated that CBD and its metabolite 7- Hydroxy cannabidiol (7-OH-CBD) reduces the risk of Covid-19 infection by activating via IRE1 α RNase and Interferon mechanisms. In general, the Covid-19 viral infection begins with the SARS-CoV-2 virus binding the receptor protein on the surface of human cells and then infiltrating by releasing the viral genes into human cells and replicating the genetic code spread in the body. The CBD extract affects the SARS-CoV-2 virus gene replication, inhibiting the expression of viral genes by up-regulating the host IRE1α ribonuclease endoplasmic reticulum (ER) stress response and interferon signaling pathways in human lung epithelial cells model resulting in viral gene deterioration and CBD, in addition to acting as an antiviral activity in the early stages of infection, also protects the body from overactive immune system response by inhibiting the cytokines production or suppressing proteins produced by cells to send signals to other cells. This intercellular communication is used in the human body's immune system. An infection, inflammation, or injury occurs different types of white blood cells in the body transmit the cytokine signal to other white blood cells and immune system cells. COVID-19 patients or patients with diabetes, hypertension, cardiovascular disease, or obesity (NCDs) usually have chronic inflammation. This condition increases the risk of developing a cytokine storm and can cause organ failure. Cytokine storm is caused by the immune system's overactive response to inflammation.

Data collection among patients from the National COVID Cohort Collaborative group found that the group of patients who used CBD in an oral solution at 100 mg/ml CBD had significantly less chance of COVID-19 infection by using positive results in SARS-CoV-2 assays. This study emphasizes the potential of CBD as a prophylactic agent for early-stage SARS-CoV-2 infection prevention and should be subject to further clinical trials.

Nowadays, many CBD-containing products are available in the market. However, the above research highlighted that other cannabinoid, such as THC, may decrease the antiviral activity of CBD. Thus, the high purity and quality of CBD extracts are the keys to another hope for further COVID-19 prevention. To ensure the purity and quality of CBD extracts, Salus Bioceutical (Thailand) has a specific laboratory for hemp research and development for improving, developing, and becoming a new leader in hemp innovation. Salus used the most advanced technology from Canada to guarantee the high purity and quality of premium graded extracts. All production processing is followed by EU-GMP standards, cooperating with specialized companies in specific hemp extraction. All customers are confident that the CBD extracts are high quality and high purity for better results. It can also be quickly delivered and sufficient to meet the customer's requirements.

References

[1] Nguyen et.al. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. SCIENCE ADVANCES. 2022; 8 (8): doi: 10.1126/sciadv.abi6110